Drugs / CT0181
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04973098 | Aug 2021 → Aug 2022 | hepatocellular carcinoma | Peking University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT0181 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04973098 ↗ |
| Modality | Cell therapy | “CT0181 humanized anti GPC3 autogenous T Cell injection” NCT04973098 ↗ |
| Target | GPC3 | “CT0181 humanized anti GPC3 autogenous T Cell injection” NCT04973098 ↗ |